Analysis of protective effects of a new UV device system for peritonitis in PD patients.

Analysis of protective effects of a new UV device system for peritonitis in PD patients. - J-UVD/PD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013942

Enrollment

230

Registered

2015-02-01

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-Stage Renal Disease (ESRD)

Interventions

Usage of a UV device named as &quot

clean flash&quot

Tsunagu&quot

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Should be included (a) or (b), and continuing PD therapy within 3 years; (a)ESRD patients continuing PD therapy with Baxter manual system or Baxter UV device system "clean flash" for PD bag exchanges or (b)ESRD patients to start PD therapy for a renal replacement therapy.

Exclusion criteria

Exclusion criteria: Should be excluded even if one of them would be positive; patients under 20 years old, patients continuing PD therapy more than 3 years, or patients on PD therapy except for Baxter system.

Design outcomes

Primary

Measure	Time frame
1. Duration until the first incidence of peritonitis 2. Incidence of total peritonitis 3. Incidence of peritonitis related to touch-contamination during bag exchanges	—

Secondary

Measure	Time frame
1. Peritoneal function (D/P Cre) 2. Residual renal function (residual Kt/V, residual CCre) 3. Technical failure (Duration of PD therapy until withdrawal from PD therapy, prognosis)	—

Countries

Japan

Contacts

Public ContactMasashi Mizuno

Nagoya University Nephrology and Renal Replacement Therapy

mmizu@med.nagoya-u.ac.jp052-744-2205

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026